GlassScriptPhysician profile
Shaghayegh Denoble
NPI 1770726564
$2,764.43
in general payments reported to CMS, 2019-2025
28 companies · $594 in 2025
The $594 reported for 2025 was more than what 84% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $372 · 2020: $156 · 2021: $102 · 2022: $252 · 2023: $815 · 2024: $474 · 2025: $594.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,506 · Education: $377.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,505.63 |
| Education | $377.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $569.96 | 2019-2023 | Orilissa, Lo Loestrin Fe, Liletta |
| Astellas Pharma US INC | $447.82 | 2023-2025 | Veozah, Myrbetriq |
| Millicent US INC | $430.02 | 2023-2025 | Femring, Intrarosa, Femlyv |
| Mayne Pharma Commercial LLC | $277.51 | 2022-2025 | |
| Pfizer INC. | $114.38 | 2021-2024 | |
| Medtronic, INC. | $96.15 | 2023 | Solitaire X |
| Biotissue Holdings INC. | $92.75 | 2024 | |
| Exeltis, USA INC. | $61.62 | 2021-2025 | Slynd |
| Evofem Biosciences, INC. | $60.95 | 2021-2024 | Phexxi |
| Hologic Sales and Service, LLC | $53.09 | 2022-2024 | Acessa Provu System |
| Organon LLC | $52.68 | 2022-2025 | Nexplanon |
| Myovant Sciences INC. | $51.35 | 2022 | |
| Fujifilm Healthcare Americas Corporation | $50.00 | 2019 | |
| Davol INC. | $45.48 | 2023 | Arista Ah Flexitip |
| Avion Pharmaceuticals | $42.05 | 2019-2023 | Balcoltra |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Therapeuticsmd, INC. | $37.51 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $37.04 | 2024-2025 | |
| Sumitomo Pharma America, INC. | $31.70 | 2024-2025 | Myfembree |
| Meditrina | $28.33 | 2023 | |
| Amag Pharmaceuticals, INC. | $26.62 | 2019 | |
| Merck Sharp & Dohme LLC | $25.97 | 2019 | |
| Allergan, INC. | $25.94 | 2019 | |
| Axonics, INC. | $24.85 | 2023 | Axonics, Bulkamid |
| Becton, Dickinson and Company | $23.64 | 2024 | Bd Onclarity |
| Lupin INC. | $15.35 | 2019 | |
| Dysis Medical, INC. | $14.45 | 2022 | |
| Aspira Women'S Health INC | $13.86 | 2020 | |
| Cumberland Pharmaceuticals, INC. | $13.36 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shaghayegh Denoble listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.